Evidence map›Paper›PMID 40411596›Full record

ArticleAnnals of hematology2025

Matching-adjusted indirect comparison of CPX- 351 in secondary Acute Myeloid Leukemia between the registrative trial and a real-life study.

Luana Fianchi, Alfonso Piciocchi, Fabio Guolo, Francesco Marchesi, Giovanni Marsili, Chiara Cattaneo, Michele Gottardi, Francesco Restuccia, Anna Candoni, Elettra Ortu La Barbera and 24 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Luana Fianchi *Dipartimento Di Diagnostica Per Immagini, Fondazione Policlinico Universitario A. Gemelli, IRCCS- Università Cattolica del Sacro Cuore, Radioterapia Oncologica Ed Ematologia, Rome, Italy. luana.fianchi@policlinicogemelli.it.
Alfonso Piciocchi *Unità Di Biostatistica Fondazione Gimema, Rome, Italy.
Fabio GuoloIRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Francesco MarchesiIRCCS Istituto Nazionale Tumori Regina Elena, Rome, Italy.
Giovanni MarsiliUnità Di Biostatistica Fondazione Gimema, Rome, Italy.
Chiara CattaneoSC Ematologia E Dipartimento Di Oncologia Clinica, A.O. Spedali Civili, Brescia, Italy.
Michele GottardiU.O.C. Oncoematologia Dipartimento Di Oncologia Istituto Oncologico Veneto (IOV)-IRCCS, Castelfranco Veneto, Italy.
Francesco RestucciaUOC Ematologia Ospedale Civile, Pescara, Italy.
Anna CandoniDepartment of Medical and Surgical Sciences, Azienda Ospedaliera Universitaria Di Modena, Università Di Modena E Reggio Emilia, Modena, Italy.
Elettra Ortu La BarberaUOC Ematologia Con Trapianto Santa Maria Goretti, Latina, Italy.
Rita FazziHematology Unit - A.O.U.P. Ospedale Santa Chiara, Pisa, Italy.
Crescenza PasciollaHaematology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Olimpia FinizioAORN Cardarelli, Naples, Italy.
Nicola FracchiollaFondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico Di Milano, Milan, Italy.
Mario DeliaAzienda Ospedaliero-Universitaria Consorziale Policlinico Di Bari, Bari, Italy.
Federica LessiEmatologia E Immunologia, Clinica Azienda Ospedaliera Di Padova, Padua, Italy.
Michela DargenioUO Ematologia E Trapianto CSE V.Fazzi, Lecce, Italy.
Valentina BonuomoDipartimento Di Scienze Cliniche E Biologiche, Università Di Torino, Turin, Italy.
Maria Ilaria Del PrincipeDipartimento Di Biomedicina E Prevenzione, Università Degli Studi Di Roma "Tor Vergata", Rome, Italy.
Patrizia ZappasodiFondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Marco PicardiEmatologia, AOU Federico II, Naples, Italy.
Claudia BasilicoAzienda Socio Sanitaria Territoriale Dei Sette Laghi, Varese, Italy.
Monica PiedimonteAOU Sant'Andrea, Rome, Italy.
Paola MinettoEmatologia E Trapianto, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Patrizia ChiusoloDipartimento Di Diagnostica Per Immagini, Fondazione Policlinico Universitario A. Gemelli, IRCCS- Università Cattolica del Sacro Cuore, Radioterapia Oncologica Ed Ematologia, Rome, Italy.
Lucia PreziosoEmatologia, Ospedale Di Parma, Parma, Italy.
Caterina BuquicchioSc Ematologia Con Trapianto, Ospedale Dimiccoli, Barletta, Italy.
Lorella MelilloEmatologia, Policlinico OU, Foggia, Italy.
Daniele ZamaPoliclinico Sant'Orsola Malpighi, Bologna, Italy.
Francesca FarinaDipartimento Di Oncologia, U.O. Ematologia E Trapianto Midollo, Istituto Scientifico San Raffaele, Milan, Italy.
Valentina ManciniDivisione Di Ematologia, Ospedale Niguarda, Milan, Italy.
Michela RondoniU.O.C. Di Ematologia, Azienda Unità Sanitaria Locale Della Romagna, Ravenna, Italy.
Alessandro BuscaSC Ematologia, Ospedale, AOU Città Della Salute E Della Scienza, Turin, Italy.
Livio PaganoDipartimento Di Diagnostica Per Immagini, Fondazione Policlinico Universitario A. Gemelli, IRCCS- Università Cattolica del Sacro Cuore, Radioterapia Oncologica Ed Ematologia, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A real-life study on CPX-351 and the standard arm ('7 + 3') of the CPX-351 registrative trial in adults with secondary Acute Myeloid Leukemia were compared by an unanchored Matching-adjusted indirect comparison (MAIC), in order to evaluate the efficacy and toxicity of CPX-351. Results of this study are important to confirm the role of CPX-351 in significantly improving survival and remission rates compared with '7 + 3' with a good safety profile in AML patients with high-risk features, a target group traditionally with a very poor prognosis. Moreover, this pilot analysis underlines the potentiality of the statistical method to compare studies with strong differences.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLeukemia, Myeloid, AcuteNeoplasms, Second PrimaryAdultAgedCytarabineDaunorubicinFemaleHumansMaleMiddle AgedPilot ProjectsRegistriesSurvival RateCPX-351CytarabineDaunorubicinCPX- 351Matching-adjusted indirect comparisonSecondary acute myeloid leukemia

Identifiers

PMID40411596
PMCPMC12141356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.